Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer

Clinical Lung Cancer

Volumn 7, Issue 6, 2006, Pages 395-400

  Ghio, Paulo ^a   Cappia, Susanna ^a   Selvaggi, Giovanni ^a   Novello, Sylvia ^a   Lausi, Paulo ^a   Zecchina, Gabriella ^a   Papotti, Marno ^a   Borasio, Piero ^a   Scagliotti, Giorgio V ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Angiogenesis; Extracellular matrix invasion; Microvessel density

Indexed keywords

CD34 ANTIGEN; PROTEIN ANTIBODY; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; VASCULOTROPIN;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA;

EID: 33745903082     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.023     Document Type: Article

References (30)

1. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9:267-285.
2. Decock J, Paridaens R, Cufer T. Proteases and metastasis: clinical relevance nowadays? Curr Opin Oncol 2005; 17:545-550.
3. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407:258-264.
4. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002; 54:203-217.
5. Wojtukiewicz MZ, Tang DG, Ben-Josef E, et al. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 1995; 55:698-704.
6. Zhang X, Hunt JL, Landsittel DP, et al. Correlation of protease-activated receptor-1 with differentiation markets in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res 2004; 10:8451-8459.
7. Heider I, Schulze B, Oswald E, et al. PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. Oncol Res 2004; 14:475-482.
8. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4:909-914.
9. YuanTC, Lin MF. Protease-activated receptor 1: a role in prostate cancer metastasis. Clin Prostate Cancer 2004; 3:189-191.
10. Rudroff C, Seibold S, Kaufmann R, et al. Expression of the thrombin receptor PAR-1 correlates with tumor cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 2002; 19:181-189.
11. Massi D, Naldini A, Ardinghi C, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 2005; 36:676-685.
12. Kamath L, Meydani A, Foss F, et al. Signalling from protease-activated receptors-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001; 61:5933-5940.
13. Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell mobility and metastasis. Mol Cancer Res 2004; 2:395-402.
14. Darmoul D, Gratio V, Devaud H, et al. Protease-activated receptor-2 in colon cancer. J Biol Chemistry 2004; 279:20927-20934.
15. Fujiwara M, Jin E, Ghazizadeh M, et al. Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells. J Histochem Cytochem 2005; 53:1121-1129.
16. Shapiro MJ, Weiss EJ, Faruqi TR, et al. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000; 275:25216-25222.
17. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998; 95:6642-6646.
18. Fujiwara M, Jin E, Ghazizadeh M, et al. Differential expression of protease-activated receptors 1, 2, and 4 on human endothelial cells from different vascular sites. Pathobiology 2004; 71:52-58.
19. Mountain FC. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-1717.
20. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A:2474-2484.
21. Jin E, Fujiwara M, Pan X, et al. Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer 2003; 97:703-713.
22. Boire A, Covic, L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120:303-313.
23. Yin YJ, Salah Z, Grisaru-Granovsky S, et al. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 2003; 23:940-944.
24. Even-Ram SC, Maoz M, Pokroy E, et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha v beta 5 integrin. J Biol Chem 2001; 276:52-62.
25. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84:579-621.
26. D'Andrea MR, Derian CK, Santulli RJ et al. Differential expression of PAR-1 and 2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001; 158:2031-2041.
27. Mineo TC, Ambrogi V, Baldi A et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004; 57:591-597.
28. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86:558-563.
29. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with stage I lung adenocarcinoma. Cancer 2002; 94:1083-1093.
30. Kuliopulos A, Covic L. Blocking receptors on the inside: pepducin-based intervention of PAR signalling and thrombosis. Life Sci 2003; 74:255-262.